WuXi Biologics (OTCPK:WXIBF) is reportedly selling its vaccine facility in Ireland to Merck (NYSE:MRK) as part of a previously announced plan to divest some of its assets. The China-based contract ...

WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

In Ireland, WuXi Biologics has sold a new vaccine plant to Merck & Co. for €500 million ($521 million). The New Jersey company was a natural buyer of the facility as it was the lone client WuXi ...

The facility, with a net book value of about $487 million, is a 15,520-square-meter, three-story vaccine manufacturing plant with 200 employees. The deal is expected to be completed in the first ...

Wuxi invested €200 million in 2019 to build the plant, which currently employs 200 people, alongside a biologics facilities it continues to operate. MSD says it will add 150 jobs to the Dundalk ...

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has ...